Debiopharm Research & Manufacturing SA, a global biopharmaceutical company based in Switzerland dedicated to curing cancer and infectious diseases, and Oncodesign Services, a leading contract research organization (CRO) specializing in drug discovery and preclinical services, announce the signing of a license agreement for the use of AbYlink™ technology for preclinical services.
AbYlink™ is a regioselective bioconjugation technology ideal for the production of conjugates for therapeutic and non-invasive diagnostic applications. Oncodesign Services will utilize this cutting-edge technology to produce antibody-chelator conjugates for preclinical studies to gain insights into the predictive efficacy of novel treatment approaches in molecular radiotherapy, and particularly radioimmunotherapy, in cancer. A joint poster demonstrating the use of the non-invasive technology in radioimmunotherapy of HER2+ tumors in animal models will be presented at the 2025 AACR Annual Meeting.
Also Read: Atreo Launches Transformative v2.0 RTSM Platform
“We have demonstrated the efficacy of this powerful technology for the rapid and covalent conjugation of any commercially available antibody with an imaging agent in a single step. Our strategic collaboration with Oncodesign Services enables broader access to and use of non-invasive imaging applications and offers biotech and pharmaceutical partners an innovative solution for integrating imaging into the development of new antibody- and ADC-based therapeutics,” commented Frédéric Lévy, Chief Scientific Officer at Debiopharm.
Aidan Synnott, CEO of Oncodesign Services, said: “We are delighted to add this cutting-edge technology to our portfolio for our customers. AbYlink™ technology offers the advantage of producing reproducible batches of bioconjugated antibodies and ADCs, ensuring the specificity and efficacy of targeted radiotherapy.”
SOURCE: Businesswire